98%
921
2 minutes
20
Within an infrastructure to monitor vaccine effectiveness (VE) against hospitalization due to COVID-19 and COVID-19 related deaths from November 2022 to July 2023 in seven countries in real-world conditions (VEBIS network), we compared two approaches: (a) estimating VE of the first, second or third COVID-19 booster doses administered during the autumn of 2022, and (b) estimating VE of the autumn vaccination dose regardless of the number of prior doses (autumnal booster approach). Retrospective cohorts were constructed using Electronic Health Records at each participating site. Cox regressions with time-changing vaccination status were fit and site-specific estimates were combined using random-effects meta-analysis. VE estimates with both approaches were mostly similar, particularly shortly after the start of the vaccination campaign, and showed a similar timing of VE waning. However, autumnal booster estimates were more precise and showed a clearer trend, particularly compared to third booster estimates, as calendar time increased after the vaccination campaign and during periods of lower SARS-CoV-2 activity. Moreover, the decrease in protection by increasing calendar time was more clear and precise than when comparing protection by number of doses. Therefore, estimating VE under an autumnal booster framework emerges as a preferred method for future monitoring of COVID-19 vaccination campaigns.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12001144 | PMC |
http://dx.doi.org/10.1017/S0950268825000317 | DOI Listing |
Vaccine
August 2025
Department of Immunization, Vaccines, and Biologicals, World Health Organization, Geneva, Switzerland. Electronic address:
As the COVID-19 pandemic has evolved, interpreting COVID-19 vaccine effectiveness (VE) has become increasingly complex due to time-varying factors that need to be disentangled, such as waning of protection and new SARS-CoV-2 variant or sub-variant emergence. Given that policymakers and regulatory authorities use COVID-19 VE data to inform COVID-19 vaccine and immunization program recommendations, the World Health Organization convened a virtual meeting on May 7, 2024. At the meeting, approaches for addressing time-varying factors were discussed using examples of COVID-19 VE studies applying a test-negative design.
View Article and Find Full Text PDFJ Med Internet Res
July 2025
Center for Primary and Community Care, Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland.
Background: To enhance patient empowerment, the Cantonal Hospital of Lucerne launched a patient portal (MyChart) in December 2019, granting patients access to their medical records, diagnoses, and laboratory results. Months later, the first COVID-19 case was reported in Switzerland, with the pandemic dramatically affecting health care services.
Objective: This analysis aims to investigate how the pattern of patient portal registrations evolved during the pandemic, with reference to the spread of COVID-19, as well as local and federal policies.
Front Immunol
July 2025
Department of Infectious Diseases Prevention and Control, Center for Disease Control and Prevention of Jiulongpo District, Chongqing, China.
Objective: This study aimed to investigate the epidemiological characteristics and determinants of breakthrough varicella (BV) cases in student populations, identify key factors influencing breakthrough infection intervals, and provide recommendations for vaccination strategy optimization.
Methods: A retrospective analysis was conducted on varicella cases and vaccination records among students in Jiulongpo District, Chongqing (2019-2023). Descriptive epidemiology methods were employed to characterize BV cases, with linear regression modeling assessing correlations between post-vaccination breakthrough intervals, primary immunization age, and the interval between two doses.
medRxiv
June 2025
Covid Surveillance Unit, The Francis Crick Institute, London, UK.
Background: The experience of the COVID-19 pandemic has differed across continents. We hypothesized that regional differences in SARS-CoV-2 immunity might explain this observation. We therefore established the WWW Consortium in Ghana, W Africa; Jamaica, W Indies; and W London.
View Article and Find Full Text PDFEpidemiol Infect
June 2025
Centre for Infectious Disease Control, https://ror.org/01cesdt21National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Lower COVID-19 vaccination coverage was observed among some populations with a migration background in the Netherlands. This study examined determinants of being unvaccinated against COVID-19 in the primary vaccination round in adults and in the 2022 autumn booster round in persons aged ≥60 years, among four populations of non-Dutch origin with below average vaccination coverage: Moroccan, Turkish, Surinamese and Dutch-Caribbean, and persons of Dutch origin. We performed a population-wide register-based study, examining associations between potential determinants and being unvaccinated using multivariable logistic regression and computing population attributable fractions.
View Article and Find Full Text PDF